Generally well-tolerated, but some may experience nausea, stomach upset, or restlessness
JCI Insight 10 , e174825 (2024)
Sep 2024 - Global pharmaceutical company Amneal Pharmaceuticals, Inc., and clinical-stage biopharmaceutical company Metsera, Inc., are accelerating next-generation medicines for obesity and metabolic diseases by joining forces with a portfolio of new weight loss medicines on efficient development and large-scale supply worldwide
Initially, a register-based study from Taiwan suggested that the administration of DPP-4 inhibitors could be associated with an increased risk of TC (Tseng, 2016)
Finally, consider account access and verification